Shareholder Alert: Ademi LLP investigates whether Checkmate Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Regeneron

Provided By PR Newswire

Last update: Apr 19, 2022

MILWAUKEE, April 19, 2022 /PRNewswire/ -- Ademi LLP is investigating Checkmate (NASDAQ:CMPI) for possible breaches of fiduciary duty and other violations of law in its transaction with Regeneron.